Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: PRNAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Ltd. filings document a foreign private issuer and development-stage biotechnology company focused on disease-modifying treatments for neurodegenerative diseases. Its Form 6-K reports provide current updates on the company’s Multiple System Atrophy program, including ATH434, the bioMUSE Natural History Study, quantitative MRI biomarker research, medical meeting presentations, and clinical or regulatory program activity.
The filing record also includes Appendix 4C quarterly cash-flow and corporate activity reports, exhibits incorporated by reference into Form S-8 and Form F-3 registration statements, governance updates, and notices related to securities matters such as consolidation or split activity. These filings describe the company’s operating progress, financing framework, board and management disclosures, risk-related development context, and capital-structure records.
Alterity Therapeutics filed a Form 6-K to disclose the appointment of Daniel O. Claassen, M.D., M.S. as Chief Medical Advisor beginning in March 2026. Dr. Claassen is a tenured professor of neurology at Vanderbilt University Medical Center and an internationally recognized expert in neurodegenerative diseases, especially movement disorders and multiple system atrophy (MSA).
He previously served as coordinating investigator for Alterity’s Phase 2 study of its lead drug candidate ATH434 in MSA and has led numerous clinical trials across academia and industry. Alterity highlights that ATH434 showed clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open-label Phase 2 study in advanced MSA, and notes it is preparing a Phase 3 pivotal trial.
Alterity Therapeutics filed a Form 6-K to disclose the appointment of Daniel O. Claassen, M.D., M.S. as Chief Medical Advisor beginning in March 2026. Dr. Claassen is a tenured professor of neurology at Vanderbilt University Medical Center and an internationally recognized expert in neurodegenerative diseases, especially movement disorders and multiple system atrophy (MSA).
He previously served as coordinating investigator for Alterity’s Phase 2 study of its lead drug candidate ATH434 in MSA and has led numerous clinical trials across academia and industry. Alterity highlights that ATH434 showed clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open-label Phase 2 study in advanced MSA, and notes it is preparing a Phase 3 pivotal trial.
Alterity Therapeutics provides a shareholder update highlighting major progress with its lead drug candidate ATH434 for Multiple System Atrophy (MSA) and outlining priorities for 2026. In 2025 the company completed its Phase 2 program in MSA, reporting “resoundingly favourable” results, with ATH434 shown to be safe and well-tolerated and to provide strong signals of efficacy, including slowing disease progression and improving mobility and orthostatic hypotension, with no drug-related serious or severe adverse events compared with placebo. Alterity is now planning a pivotal Phase 3 program in MSA and expects to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the Phase 3 trial design. The company also reports governance and leadership enhancements, including appointing Julian Babarczy as Chair of the Board and expanding its management team in investor relations and corporate strategy to support potential future commercialization and increased business development.
Alterity Therapeutics provides a shareholder update highlighting major progress with its lead drug candidate ATH434 for Multiple System Atrophy (MSA) and outlining priorities for 2026. In 2025 the company completed its Phase 2 program in MSA, reporting “resoundingly favourable” results, with ATH434 shown to be safe and well-tolerated and to provide strong signals of efficacy, including slowing disease progression and improving mobility and orthostatic hypotension, with no drug-related serious or severe adverse events compared with placebo. Alterity is now planning a pivotal Phase 3 program in MSA and expects to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the Phase 3 trial design. The company also reports governance and leadership enhancements, including appointing Julian Babarczy as Chair of the Board and expanding its management team in investor relations and corporate strategy to support potential future commercialization and increased business development.